I would think that there almost needs to be two trials. One focused on late stage patients and one where B is administered earlier to prevent the “late stage” from ever occurring. Or could these two be accomplished with the same trial?
SolidStrategist said,
What does everyone think will be the endpoint targeted when this goes to trial? Overall effect on mortality? Patients who successfully come off the vent? Prevention of patients deteriorating to the point they need a vent?